Erasca to Present at Upcoming Investor Conferences
June 01, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor
May 31, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting
May 25, 2023 17:00 ET
|
Erasca, Inc.
Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer (CRC) showed a 40% (2/5) response rate; continued evaluation...
Erasca Further Strengthens Business Leadership with Two Key Promotions
May 16, 2023 08:00 ET
|
Erasca, Inc.
David Chacko, M.D., previously Erasca’s Chief Financial Officer, has been promoted to the dual position of Chief Financial Officer and Chief Business Officer Nik Chetwyn, Ph.D., previously Erasca’s...
Erasca Reports First Quarter 2023 Financial Results and Business Updates
May 15, 2023 16:01 ET
|
Erasca, Inc.
Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal Phase 3 SEACRAFT-2 trial for naporafenib in patients with NRASm melanoma expected to initiate in H1...
Erasca to Present at the Bank of America Securities 2023 Health Care Conference
May 02, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma
May 01, 2023 08:00 ET
|
Erasca, Inc.
ERAS-801 has demonstrated broad preclinical activity against oncogenic EGFR variants and wildtype alterations Initial THUNDERBBOLT-1 Phase 1 data in patients with recurrent GBM expected in H2 2023 ...
Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
April 26, 2023 17:00 ET
|
Erasca, Inc.
SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma
April 25, 2023 08:00 ET
|
Erasca, Inc.
Promising preliminary antitumor activity with the combination demonstrated in heavily pretreated patients 47% ORR, 5.5 months mPFS observed with preferred combination dose of naporafenib 200 mg BID...
Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting
April 18, 2023 09:00 ET
|
Erasca, Inc.
ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic resistance Combination was well-tolerated; supports ‘three weeks on, one week...